RxDoctor Payments Data

Eric Lutsky, DO

Internal Medicine · New York, NYNPI 1477530582

Payments from drug & device makers

$26,007in general payments, 2019–2025

Across 62 payments — averaging $419.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Kaleo, Inc.$25K
  • Viiv Healthcare Company$263
  • Lilly USA, LLC$234
  • Gilead$146
  • Novo Nordisk$78
  • Merck$71
  • plus $461 from 15 others

What the payments were for

  • Food & beverage$1,2415%
  • Education$120%
  • Other$24,75495%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$26,007 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$50,881
Medicare patients
125
Services billed
602

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JulucaDolutegravir/Rilpivirine62$252,040
MounjaroTirzepatide73$88,262
OtezlaApremilast14$60,874
BiktarvyBictegrav/Emtricit/Tenofov Ala13$47,423
EliquisApixaban16$17,335
OzempicSemaglutide13$12,390
SynthroidLevothyroxine Sodium15$1,578
Rosuvastatin Calcium86$1,385
PaxlovidNirmatrelvir/Ritonavir17$1,377
Telmisartan54$1,227
Amlodipine Besylate117$662
Atorvastatin Calcium77$661
Albuterol Sulfate HfaAlbuterol Sulfate18$603
Metoprolol Succinate46$506
ValacyclovirValacyclovir Hcl11$491

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyJuluca$263$252,04062 claims
Lilly USA, LLCMounjaro$234$88,26273 claims
GileadBiktarvy$146$47,42313 claims
PfizerEliquis, Paxlovid$28$18,71233 claims
Novo NordiskOzempic$78$12,39013 claims
AbbVieSynthroid$51$1,57815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →